SECTION 4: FORMULARY PROCESSES

SECTION 4.2: MANAGED INTRODUCTION OF A NEW ONCOLOGY MEDICINE IN NHS GREATER GLASGOW AND CLYDE

The process that a new oncology medicine has to follow prior to being added to the GGC Formulary is outlined below:

1. EUROPE / UK STAGE
   European Medicines Agency (EMA) or Medicines and Healthcare Regulatory Authority (MHRA)

2. NHS SCOTLAND STAGE
   Scottish Medicines Consortium (SMC) or National Institute for Health and Clinical Excellence (NICE)

3. REGIONAL (WoS) STAGE
   Regional Cancer Advisory Group (RCAG) Prescribing Advisory Subgroup
   (via ADTC Formulary and New Drugs Subcommittee)

4. LOCAL (NHSGGC) STAGE
   Area Drug and Therapeutics Committee (ADTC)

5. MANAGEMENT STAGE
   Prescribing Management Group (PMG)

6a. Formulary status

**Licensing process:**
- Medicine required to demonstrate:
  - Quality
  - Efficacy
  - Safety
- Total time from the original patent approval of the new compound to completion of the requirements of the licensing authority may be 10 – 12 years.

**Clinical and cost-effectiveness review:**
- SMC advice to all NHS Boards, as close as possible to medicine launch
- NICE advice typically follows after several months/years
  - Only Multiple Technology Appraisals are applicable to NHS Scotland
- Medicine requires to demonstrate:
  - Clinical effectiveness
  - Cost-effectiveness (value for money)
- Time for completion: 3 – 4 months

**Regional practice implications:**
- Consultation with local experts / MCN
- Medicine requires to demonstrate:
  - SMC acceptance
  - Advantage(s) over existing therapy
  - Support from local specialists
  - Role for medicine in context with existing clinical practice
  - Treatment protocol/guidelines with care management plan
  - Budget impact analysis
- Time for completion: 2 – 3 months

**Formulary management:**
- Implementation plan and communication to prescribers
- Medicine requires to demonstrate insignificant financial or service implications, otherwise referral to PMG is necessary
- Time for completion: 1 – 2 months

**Planning and resource management:**
- Horizon scanning
- Financial monitoring
- Focus on selected new developments which require managed introduction due to cost, service redesign or other resource implications.
- Time for completion: 4 – 6 weeks

**Formulary status:**
- Preferred List (suitable for initiation by all prescribers)
- Total Formulary (usually medicines that are for Specialist use)
- Non-Formulary (use subject to approval via IPTR/NF process)
- Time for completion: immediate
6b. Formulary status

7. INDIVIDUAL PATIENT TREATMENT REQUEST
- Policy 5.2
- Prescription approval required on a case by case basis
- Application made by patient’s consultant
- Consideration by Directorate panel

8. APPEAL (WHERE APPROPRIATE)
- Policy 5.3
- Raised where consultant believes there are grounds for re-examination of the evidence or the process
- Case made by consultant, with patient support
- Consideration by Board panel

9. CO-PAYMENT
- Policy 5.5
- Individual patient / family decision in collaboration with treating consultant
- Opportunity to consider private funding for treatment; various options for care provision in the private sector, depending on the medicine and the clinical circumstances

Preferred list or Total Formulary medicines
- Prescribe in accordance with Formulary status including any restrictions
- Oncology medicines are typically listed in the Total Formulary, for prescription by specialists only

Prescription can proceed immediately
- Prescribe in accordance with IPTR panel decision
- If time/quantity limited then further application may be required

Prescription can proceed immediately
- Prescribe in accordance with appeal panel decision

Prescription can proceed immediately on receipt of funding
- Refund will be made if change in national advice during course of treatment (calculated from point at which advice in public domain)

NHS OPTIONS COMPLETE
STAGES FOR ADDITION OF A NEW CANCER MEDICINE TO THE DRUG FORMULARY in NHS GREATER GLASGOW & CLYDE (*)

STEP 1
Medicines regulation aims to protect the patient interest. For a medicine to get a licence, it must show that it works, is safe, and is of good quality. The company which is granted the licence can then promote and sell their medicine in the UK and set a price for that medicine.

STEP 2
The company which makes the medicine presents its case to SMC. This step looks at the health gain from the medicine for the money it costs. This often means looking at the new medicine side by side with medicines already in use. It should indicate if the new medicine offers good value for money. The SMC may say it should only be prescribed by certain types of doctors or in particular groups of patients. SMC may also say a medicine should not be used in Scotland and we would generally follow this advice.

NICE/NHS HIS may review the same medicine. This might be the medicine on its own or a group of medicines for the same disease. An example of this is medicines for the treatment of renal cancer. This advice may say which medicine should be used first, or second etc. Rarely, certain types of advice from NICE/NHS HIS will overrule earlier SMC advice. This is thought to make good sense as more may be known about the medicine by the time of the NICE review.

STEP 3
Advice from SMC/NHS HIS on cancer medicines goes to the Regional Prescribing Advisory Group. Local specialists for the relevant tumour type look over the advice and decide how and if they wish to use the medicine in patients in the West of Scotland. They write a set of guidelines for use which explains when, how, where and in whom a medicine should be used. If this means a change which will increase costs or time needed (e.g. nurse, pharmacy or patient time in a hospital bed) or need special equipment or tests, then this is examined in more detail. This group makes sure that the local guidelines fit with the national advice.

STEP 4
ADTC through the FND takes the advice from the regional group and the Formulary is updated as necessary. If there are high costs or need for a new service to be set up then this will be sent on to the PMG to decide how this should be handled.

STEP 5 (only required for high cost/new service)
PMG will review cases where high costs are likely to result and decide if this was expected (part of the medicines plan) or if extra funding needs to be sought. If changes in the service are needed then PMG will look at how these changes might be managed. There may be a short delay to sort this, before the medicine is added to the Formulary, but this will be kept to a minimum.

STEP 6
Once a medicine is added to the Formulary, specialists can then use the medicine according to local arrangements. Medicines not on the Formulary can still be prescribed, but it is expected that there will be infrequent use via the IPTR process where the patient meets the agreed criteria.

IN SUMMARY
- Medicines regulation seeks to achieve the right balance between protecting the patient from harm and allowing access to new medicines.
- A safe and effective medicine gets a licence via a European or UK agency.
- National (NHS Scotland) review indicates if it is "good value for money".
- The regional advisory group decides if this is a medicine it wants to use.
- The local Health Board decides if everything is in place for this to go ahead within local practice.
  - If yes, the medicine is added to the Formulary; clinicians decide if they want to prescribe the medicine for individual patients.
SECTION 4: FORMULARY PROCESSES

- If no, the medicine is excluded from Formulary; clinicians need to adopt additional procedures and seek management approval to prescribe for individual patients.

STEP 7
If the treating consultant feels that an individual patient’s case is different in a way which means they may do better than others with the same condition then they can request permission to use through an Individual Patient Treatment Request (IPTR). The case will be considered by a panel of specialists.

STEP 8
If the IPTR is not approved then an appeal can be lodged if supported by the treating clinician. The same evidence is then reviewed by a different panel.

STEP 9
If the appeal is not approved and there is still a desire to use the treatment then the patient has the option to fund. If this cannot be done in the private sector then arrangements can be made to proceed within NHS care but payment of the full cost of the treatment has to be made in advance. Refunds can be provided if appropriate.

* See following page for definitions and abbreviations
DEFINITIONS

European Medicines Agency (EMEA) and the Medicines and Healthcare products Regulatory Agency (MHRA) are the European Union body (EMEA) and the UK Government agency (MHRA) who are responsible for medicines control. Medicines (and medical devices) must show they are good quality; they do what is meant and are suitably safe. The two organisations work in partnership. The EMEA has responsibility for certain types of medicines (e.g. for cancer, diabetes, biological treatments) across all the member countries. The MHRA retains responsibility for the majority of medicines within the UK.

Scottish Medicines Consortium (SMC) is made up of representatives from across all the Scottish Health Boards and from a range of professions: doctors, pharmacists, nurses, health economists, managers and lay people on behalf of patient interest groups. It provides advice to the NHS in Scotland about new medicines and about their "value for money". They may also identify the patients who could benefit most from the new treatment. This advice comes early after the medicine is marketed in the UK. It helps to make sure that medicines are equally available to patients across Scotland.

National Institute for Health and Clinical Effectiveness (NICE) provides guidance on the prevention and treatment of ill health for England and Wales.

Health Improvement Scotland (NHS HIS) is the Scottish body which comments on NICE advice on new medicines (called Multiple Technology Assessments) and says how these fit into practice in NHS Scotland. (NICE also produces other types of advice but these are not all adopted in Scotland).

Regional (West of Scotland) Cancer Advisory Group (RCAG), Prescribing Advisory Subgroup looks at the advice above (from SMC and NICE/NHS HIS) for medicines used in the care of patients with cancer.

Area Drug and Therapeutics Committee (ADTC) advises the Health Board on everything to do with medicines. The overall aim is to promote effective use of medicines in NHS Greater Glasgow & Clyde (NHS GGC) as part of the total care.

The Formulary and New Drugs Subcommittee (FND) of ADTC is the group which has responsibility for dealing with new medicines and this group takes suggestions to ADTC for approval.

Managed Clinical Network (MCN) is a specialist planning group which involves different health professionals, managers and members of the public. There are MCNs for all the major tumour types.

Prescribing Management Group (PMG): manages the financial aspects of prescribing, planning for new medicines and watching over how they are used. It aims to get the maximum benefit from the high spend on medicines (over £350m in 2012/13) for the whole population which it serves.

Medicines Formulary is a limited list of medicines agreed for use in NHS GGC, chosen because they are shown to work effectively, specialists find them useful and patients find them acceptable. Formulary medicines therefore represent good value for money compared with other medicines that do the same job. All prescribers are expected to stick to this list for most patients. There can sometimes be special reasons why a medicine from outside this list is the best choice for a patient. Special procedures allow for such exceptions.

This local "Formulary" should not be confused with the British National Formulary which is a list of all medicines licensed for use in the UK.